

**Amendments To The Claims**

Please amend claims 12-17 and add new claim 33, as set forth below.

Please cancel claims 1-11 and 18-32.

The current listing of claims replaces all prior listings.

**Listing of Claims**

1-11. (Canceled)

12. (Currently amended) A method for introducing a CNS cell into a murine or primate ~~mammal, comprising administering to a mammal a cell produced by a method comprising:~~

- (a) plating human CNS progenitor cells on a surface that permits proliferation, wherein the ~~[[said]]~~ surface is a ~~being~~ tissue culture plastic or a surface treated with fibronectin;
- ~~[[b]] adding serum-free growth medium to the cells;~~
- ~~(b) [[c]]~~ allowing the CNS progenitor cells to proliferate in ~~[[the]]~~ serum-free medium;
- ~~(c) [[d]]~~ transfecting the cells with DNA encoding a selectable marker and regulatable growth-promoting gene, ~~wherein the growth-promoting gene is selected from the group consisting of SV40 large T antigen, v-myc, N-myc, c-myc, p53, polyoma large T antigen, Ela adenovirus and E7 protein of human papilloma virus;~~
- ~~(d) [[e]]~~ passaging the transfected cells onto a substrate; and
- ~~(e) [[f]]~~ adding serum-free growth medium containing one or more proliferation-enhancing factors to the transfected cells, wherein ~~[[said]]~~ the proliferation-enhancing factors are selected from the group consisting of FGF-2, PDGF, EGF, medium conditioned by perpetualized adult rat hippocampal progenitor cells, and a combination thereof, ~~therefrom thereby~~ producing ~~[[a]]~~ conditionally-immortalized human CNS progenitor cells, and administering the cells to the murine or primate.

13. (Currently amended) A method for introducing a CNS cell into a murine or primate

~~mammal~~, comprising administering to a murine or primate ~~mammal~~ a conditionally-immortalized clonal human CNS progenitor cell which upon appropriate conditions can ~~enable~~ of differentiate[[ion]] into neurons and astrocytes.

14. (Currently amended) A method for treating a subject patient, ~~comprising administering to a patient a cell produced by a method comprising:~~

- (a) plating human CNS progenitor cells on a surface that permits proliferation, wherein the [[said]] surface is a ~~being~~ tissue culture plastic or a surface treated with fibronectin;
- ~~(b) adding serum-free growth medium to the cells;~~
- ~~(b)[[c]]~~ allowing the CNS progenitor cells to proliferate in [[the]] serum-free medium;
- ~~(c)[[d]]~~ transfecting the cells with DNA encoding a selectable marker and regulatable growth-promoting gene, ~~wherein the growth-promoting gene is selected from the group consisting of SV40 large T antigen, v-myc, N-myc, c-myc, p53, polyoma large T antigen, Ela adenovirus and E7 protein of human papilloma virus;~~
- ~~(d)[[e]]~~ passaging the transfected cells onto a substrate; and
- ~~(e)[[f]]~~ adding serum-free growth medium containing one or more proliferation-enhancing factors to the transfected cells, wherein the [[said]] proliferation-enhancing factors are selected from the group consisting of FGF-2, PDGF, EGF, medium conditioned by perpetualized adult rat hippocampal progenitor cells, and a combination thereof, ~~therefrom~~ thereby producing [[a]] conditionally-immortalized human CNS progenitor cells, and administering the cells to the subject.

15. (Currently amended) A method for treating a subject patient, comprising administering to a mammal in need thereof a conditionally-immortalized clonal human CNS progenitor cell which upon appropriate conditions can ~~enable~~ of differentiate[[ion]] into neurons and astrocytes.

16. (Currently amended) The [[A]] method of ~~according to~~ claim 15, wherein the subject patient is afflicted with a pathological condition where neurons have degenerated.

17. (Currently amended) The [[A]] method of ~~according to~~ claim 16, wherein the pathological condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and traumatic head injury.

18-32. (Canceled)

33. (New) The method of claim 12 or 14, wherein the substrate is fibronectin, polyornithine, laminin, or a combination thereof.